

## WHAT IS CLAIMED IS:

- 10
1. A pharmaceutical composition in a closed container, said composition comprising a meiosis activation substance having a low oxygen content, and wherein said closed container is capable of maintaining the low content of oxygen.
2. The pharmaceutical composition in a closed container according to claim 1, wherein the low oxygen content is below about 0.01 moles oxygen per liter of the volume of the container.
- 15 3. The pharmaceutical composition in a closed container according to claim 1, wherein the low oxygen content is below about 0.001 moles of oxygen per liter of the volume of the container.
- 20 4. The pharmaceutical composition in a closed container according to claim 1, wherein the low oxygen content is below about 0.0001 moles of oxygen per liter of the volume of the container.
- 25 5. A pharmaceutical composition in a closed container comprising:  
(i) a solid composition of a meiosis activation substance,  
(ii) an additive,  
(iii) an atmosphere with a low oxygen content, and  
wherein the closed container is capable of maintaining the low content of oxygen.
- 30 6. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition of a meiosis activation substance has a high aqueous solubility.

10058224.020502

7. The pharmaceutical composition in a closed container according to claim 5, wherein the oxygen content of the atmosphere is below 10%.
8. The pharmaceutical composition in a closed container according to claim 5, wherein the oxygen content of the atmosphere is below 5%.
9. The pharmaceutical composition in a closed container according to claim 5, wherein the oxygen content of the atmosphere is below 1%.
10. The pharmaceutical composition in a closed container according to claim 5, wherein the atmosphere contains over 90% nitrogen or argon.
11. The pharmaceutical composition in a closed container according to claim 5, wherein the atmosphere contains over 99% nitrogen or argon.
12. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition has a water content below about 10%.
13. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition has a water content below about 5%.
14. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition has a water content below about 1%.
15. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition has an organic solvent content below about 10%.
16. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition has an organic solvent content below about 5%.

10068224.020502

17. The pharmaceutical composition in a closed container according to claim 5, wherein the solid composition has an organic solvent content below about 1%.

5 18. The pharmaceutical composition in a closed container according to claim 5, wherein the meiosis activation substance content is below about 10% by weight.

19. The pharmaceutical composition in a closed container according to claim 5, wherein the meiosis activation substance content is below about 2% by weight.

10

20. The pharmaceutical composition in a closed container according to claim 5, wherein the meiosis activation substance content is below about 1% by weight.

21. The pharmaceutical composition in a closed container according to claim 1, wherein  
15 the meiosis activation substance is a compound exhibiting a percentage germinal vesicle breakdown which is 50% higher than a control.

22. The pharmaceutical compositions in a closed container according to claim 1,  
wherein the meiosis activation substance is selected from 4,4-dimethyl-5 $\alpha$ -cholesta-8,14,24-  
20 triene-3 $\beta$ -ol; 4,4-dimethyl-5 $\alpha$ -cholest-8,14,24-trien-3 $\beta$ -ol hemisuccinate; 5 $\alpha$ -cholest-8,14-  
dien-3 $\beta$ -ol; 5 $\alpha$ -cholest-8,14-dien-3 $\beta$ -ol hemisuccinate; (20S)-cholest-5-en-3 $\beta$ ,20-diol; 3 $\beta$ -  
hydroxy-4,4-dimethyl-5 $\alpha$ -chola-8,14-dien-24-oic acid-N-(methionine) amide; cholest-5-en-  
16 $\beta$ -ol; and (20S)-20-[(piperidin-1-yl)methyl]-4,4-dimethyl-5 $\alpha$ -pregna-8,14-dien-3 $\beta$ -ol.

23. The pharmaceutical composition in a closed contained according to claim 5, wherein  
25 the additive is a protein or a phosphoglyceride.

24. The pharmaceutical composition in a closed container according to claim 23,  
wherein the protein is serum albumin.

30

1006334 020502

25. The pharmaceutical composition in a closed container according to claim 24, wherein the serum albumin is human serum albumin or recombinant form human serum albumin.

5 26. The pharmaceutical composition in a closed container according to claim 5, wherein the additive content is above about 90%.

27. The pharmaceutical composition in a closed container according to claim 5, wherein the additive content is above about 98%.

10

28. The pharmaceutical composition in a closed container according to claim 5, wherein the additive content is above about 99%.

15 29. The pharmaceutical composition in a closed container according to claim 5, said container having one or more hollow spaces and wherein at least one hollow spaces contains

- (i) the solid composition of a meiosis activation substance with a high aqueous solubility,
- (ii) the additive, and
- (iii) the atmosphere with a low oxygen content.

20

30. The pharmaceutical composition in a closed container according to claim 5, wherein an aqueous media is added to the solid composition to form an aqueous solution.

25 31. The pharmaceutical composition in a closed container according to claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above about 100 µg/ml.

30 32. The pharmaceutical composition in a closed container according to claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above about 10 µg/ml.

1006324 020502

33. The pharmaceutical composition in a closed container according to claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above about 1 µg/ml.

5

34. The pharmaceutical composition in a closed container according to claim 30, wherein the meiosis activation substance in the aqueous solution is in a concentration above about 0.001 µg/ml.

10 35. The pharmaceutical composition in a closed container according to claim 30, wherein the aqueous media has an organic solvent content of less than about 0.1%.

36. The pharmaceutical composition in a closed container according to claim 30, wherein the aqueous media has an organic solvent content of less than about 0.05%.

15

37. A process for preparing a pharmaceutical composition in a closed container, comprising

- a) preparing a solid composition comprising a meiosis activation substance and an additive;
- b) adding the solid composition to the container;
- 20 c) freeze drying the composition; and
- d) closing the container *in vacuo*.

38. The process according to claim 37, wherein the preparation of the solid composition is performed *in vacuo*.

25

39. The process according to claim 37, wherein the preparation of the solid composition is in an atmosphere having a low content of oxygen.

1006324-020502

40. A process for preparing a pharmaceutical composition in a closed container, said process comprising:

- a) preparing a solid composition comprising a meiosis activation substance and an additive;
- b) filling the solid composition into the container;
- 5 c) filling the container with an atmosphere having a low content of oxygen; and
- d) closing the container.

41. The process according to claim 40, wherein the solid composition is prepared in an atmosphere having a low content of oxygen.

10

42. A process for increasing the stability of a pharmaceutical composition in a closed container comprising:

- a) preparing a solid composition comprising a meiosis activation substance having a low content of oxygen and an additive;
- 15 b) filling the solid composition into the container;
- c) filling the container with an atmosphere having a low content of oxygen; and
- d) closing the container.

20

20050224-020502